Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Puma Biotechnology (NQ: PBYI )

4.950 -0.120 (-2.37%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 256,652
Open 5.050
Bid (Size) 4.920 (17)
Ask (Size) 5.500 (1)
Prev. Close 5.070
Today's Range 4.900 - 5.170
52wk Range 2.130 - 7.730
Shares Outstanding 47,509,765
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
7 Stocks Under $15 Predicted to Boom in the Next 2 Years
Discover seven promising stocks priced under $15, leading in sectors like financial services, biotechnology, and energy. 
Via InvestorPlace
Puma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire

Performance

YTD
+9.39%
+9.39%
1 Month
-6.25%
-6.25%
3 Month
+3.88%
+3.88%
6 Month
+101.22%
+101.22%
1 Year
+87.50%
+87.50%

More News

Read More
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Earnings Scheduled For February 29, 2024
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
3 small-cap biotechs with potential breakthroughs in 2024
Via MarketBeat
Topics Bankruptcy
Exposures Financial Legal
3 Strong Buy Stocks Under $5: January 2024
Via InvestorPlace
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Third Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment Conference
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
From Puma Biotechnology, Inc.
Via Business Wire
Puma Biotechnology Reports Second Quarter Financial Results
From Puma Biotechnology, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.